JP2002516282A - 難治性鬱病の処置のための組合せ治療 - Google Patents

難治性鬱病の処置のための組合せ治療

Info

Publication number
JP2002516282A
JP2002516282A JP2000550487A JP2000550487A JP2002516282A JP 2002516282 A JP2002516282 A JP 2002516282A JP 2000550487 A JP2000550487 A JP 2000550487A JP 2000550487 A JP2000550487 A JP 2000550487A JP 2002516282 A JP2002516282 A JP 2002516282A
Authority
JP
Japan
Prior art keywords
treatment
component
effective amount
severe depression
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000550487A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002516282A5 (https=
Inventor
ゲイリー・デニス・トルフソン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of JP2002516282A publication Critical patent/JP2002516282A/ja
Publication of JP2002516282A5 publication Critical patent/JP2002516282A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Percussion Or Vibration Massage (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Compositions Of Oxide Ceramics (AREA)
JP2000550487A 1998-05-22 1999-05-21 難治性鬱病の処置のための組合せ治療 Pending JP2002516282A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8644498P 1998-05-22 1998-05-22
US60/086,444 1998-05-22
PCT/US1999/011276 WO1999061027A1 (en) 1998-05-22 1999-05-21 Combination therapy for treatment of refractory depression

Publications (2)

Publication Number Publication Date
JP2002516282A true JP2002516282A (ja) 2002-06-04
JP2002516282A5 JP2002516282A5 (https=) 2006-07-06

Family

ID=22198612

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000550487A Pending JP2002516282A (ja) 1998-05-22 1999-05-21 難治性鬱病の処置のための組合せ治療

Country Status (24)

Country Link
EP (1) EP0958824A3 (https=)
JP (1) JP2002516282A (https=)
KR (1) KR20010043730A (https=)
CN (1) CN1154496C (https=)
AU (1) AU761510B2 (https=)
BR (1) BR9911049A (https=)
CA (1) CA2332814C (https=)
CZ (1) CZ20004279A3 (https=)
EA (1) EA004539B1 (https=)
HK (1) HK1040055B (https=)
HR (1) HRP20000797A2 (https=)
HU (1) HUP0101901A3 (https=)
ID (1) ID26861A (https=)
IL (1) IL139592A (https=)
MY (1) MY127938A (https=)
NO (1) NO20005885L (https=)
NZ (1) NZ507980A (https=)
PL (1) PL344331A1 (https=)
SK (1) SK17512000A3 (https=)
TR (1) TR200003443T2 (https=)
TW (1) TWI226829B (https=)
UA (1) UA78181C2 (https=)
WO (1) WO1999061027A1 (https=)
ZA (1) ZA200006815B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006517571A (ja) * 2003-02-14 2006-07-27 ピエール、ファーブル、メディカマン 薬剤を製造するためのミルナシプランの（１ｓ，２ｒ）エナンチオマーの使用
JP2009506069A (ja) * 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6174882B1 (en) * 1998-11-23 2001-01-16 Sepracor Inc. 2-hydroxymethylolanzapine compositions and methods
SI1237553T1 (sl) * 1999-12-06 2006-06-30 Lundbeck & Co As H Kombinacija inhibitorja ponovnega navzema serotonina in antagonista 5-ht 2c?, inverznega agonista ali delnega agonista
UA77650C2 (en) * 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
JP2004517112A (ja) * 2001-01-02 2004-06-10 ファルマシア・アンド・アップジョン・カンパニー 新規薬物コンビネーション
AU2003268026A1 (en) 2002-07-30 2004-02-16 Peter Migaly Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
GB0229583D0 (en) * 2002-12-19 2003-01-22 Cipla Ltd A process for preparing duloxetine and intermediates for use therein
CN1989968B (zh) 2002-12-27 2011-05-11 大塚制药株式会社 用于治疗情绪障碍的喹诺酮衍生物和5-羟色胺再摄取抑制剂
AR042806A1 (es) 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
AU2004269858A1 (en) * 2003-09-04 2005-03-17 H. Lundbeck A/S The combination of a serotonin reuptake inhibitor and Loxapine
SI1668014T1 (sl) 2003-09-17 2009-06-30 Janssen Pharmaceutica Nv Kondenzirane heterociklične spojine kot modulatorji serotoninskih receptorjev
WO2005053703A1 (en) 2003-12-02 2005-06-16 Leslie James Sheldon Combination therapy for dementia, depression and apathy
EP1696896A2 (en) * 2003-12-15 2006-09-06 H. Lundbeck A/S The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist
US7598255B2 (en) * 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
EP2044043B2 (en) 2006-06-16 2021-03-03 H. Lundbeck A/S 1- ý[- (2, 4-dimethylphenylsulfanyl) -phenyl]piperazine hydrobromide as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment
PL2120878T3 (pl) * 2007-02-09 2015-01-30 Alphapharm Pty Ltd Postać dawkowania zawierająca dwa czynne składniki farmaceutyczne o różnych postaciach fizycznych
TWI432194B (zh) * 2007-03-20 2014-04-01 Lundbeck & Co As H ４-〔２-（４-甲基苯硫基）苯基〕哌啶之新穎治療用途
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
CN105769875A (zh) * 2014-12-22 2016-07-20 扬子江药业集团上海海尼药业有限公司 复方奥氮平盐酸氟西汀胶囊的制备方法
CN108938645A (zh) * 2018-08-24 2018-12-07 山西医科大学第医院 一种抗精神病药物组合物
CN111084778B (zh) * 2019-12-31 2022-06-24 北京鑫开元医药科技有限公司 一种奥氮平盐酸氟西汀胶囊及其制备方法
CN114569566A (zh) * 2020-12-02 2022-06-03 四川科瑞德制药股份有限公司 一种盐酸米那普仑制剂的制备方法
ES3054324A1 (es) * 2024-07-12 2026-02-02 Univ Malaga Galanina (1-15) y Fluoxetina en el tratamiento de la depresión resistente al tratamiento

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8072691A (en) * 1990-06-28 1992-01-23 Beecham Group Plc Pharmaceutical preparations
FR2716680B1 (fr) * 1994-02-25 1996-04-05 Adir Nouveaux dérivés de benzodioxane, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
WO1997033577A1 (en) * 1996-03-11 1997-09-18 Eli Lilly And Company Method for treating bipolar disorder
WO1997035586A1 (en) * 1996-03-25 1997-10-02 Eli Lilly And Company Method for treating pain
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006517571A (ja) * 2003-02-14 2006-07-27 ピエール、ファーブル、メディカマン 薬剤を製造するためのミルナシプランの（１ｓ，２ｒ）エナンチオマーの使用
JP2010090143A (ja) * 2003-02-14 2010-04-22 Pierre Fabre Medicament 薬剤を製造するためのミルナシプランの（１ｓ，２ｒ）エナンチオマーの使用
JP2009506069A (ja) * 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生

Also Published As

Publication number Publication date
EA200001218A1 (ru) 2001-06-25
IL139592A0 (en) 2002-02-10
HK1040055A1 (en) 2002-05-24
HUP0101901A3 (en) 2002-06-28
IL139592A (en) 2005-08-31
CN1154496C (zh) 2004-06-23
EP0958824A2 (en) 1999-11-24
NO20005885D0 (no) 2000-11-21
WO1999061027A1 (en) 1999-12-02
SK17512000A3 (sk) 2002-02-05
EA004539B1 (ru) 2004-06-24
AU761510B2 (en) 2003-06-05
CA2332814C (en) 2008-11-04
KR20010043730A (ko) 2001-05-25
AU4008699A (en) 1999-12-13
CZ20004279A3 (cs) 2001-09-12
CN1311681A (zh) 2001-09-05
PL344331A1 (en) 2001-11-05
NZ507980A (en) 2003-10-31
UA78181C2 (en) 2007-03-15
HRP20000797A2 (en) 2001-10-31
BR9911049A (pt) 2001-02-06
EP0958824A3 (en) 1999-12-01
MY127938A (en) 2007-01-31
ZA200006815B (en) 2002-01-14
CA2332814A1 (en) 1999-12-02
NO20005885L (no) 2001-01-17
HK1040055B (zh) 2005-04-01
TR200003443T2 (tr) 2001-03-21
HUP0101901A2 (hu) 2001-11-28
TWI226829B (en) 2005-01-21
ID26861A (id) 2001-02-15

Similar Documents

Publication Publication Date Title
JP2002516282A (ja) 難治性鬱病の処置のための組合せ治療
AU756468B2 (en) Combination therapy for treatment of bipolar disorders
EP0830864B1 (en) Combination therapy for treatment of psychoses
US6960577B2 (en) Combination therapy for treatment of refractory depression
JP2002515435A (ja) 鬱病処置のための組合せ治療
US20030027817A1 (en) Combination therapy for treatment of bipolar disorders
MXPA00011353A (es) Uso de olanzapida en combinación con fluoxetina para terapia de la depresión refractaria
MXPA00011354A (en) Combination therapy for treatment of bipolar disorders
EP1256345A1 (en) Combination therapy for treatment of psychoses
HK1009755B (en) Combination therapy for treatment of psychoses

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060517

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060517

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090721

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20090917

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091019

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20091222